首页> 外文OA文献 >Expansion, harvest and cryopreservation of human mesenchymal stem cells in a serum-free microcarrier process
【2h】

Expansion, harvest and cryopreservation of human mesenchymal stem cells in a serum-free microcarrier process

机译:无血清微载体过程中人间充质干细胞的扩增,收获和冷冻保存

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Human mesenchymal stem cell (hMSC) therapies are currently progressing through clinical development, driving the need for consistent, and cost effective manufacturing processes to meet the lot-sizes required for commercial production. The use of animal-derived serum is common in hMSC culture but has many drawbacks such as limited supply, lot-to-lot variability, increased regulatory burden, possibility of pathogen transmission, and reduced scope for process optimization. These constraints may impact the development of a consistent large-scale process and therefore must be addressed. The aim of this work was therefore to run a pilot study in the systematic development of serum-free hMSC manufacturing process. Human bone-marrow derived hMSCs were expanded on fibronectin-coated, non-porous plastic microcarriers in 100mL stirred spinner flasks at a density of 3×10cells.mL in serum-free medium. The hMSCs were successfully harvested by our recently-developed technique using animal-free enzymatic cell detachment accompanied by agitation followed by filtration to separate the hMSCs from microcarriers, with a post-harvest viability of 99.63±0.03%. The hMSCs were found to be in accordance with the ISCT characterization criteria and maintained hMSC outgrowth and colony-forming potential. The hMSCs were held in suspension post-harvest to simulate a typical pooling time for a scaled expansion process and cryopreserved in a serum-free vehicle solution using a controlled-rate freezing process. Post-thaw viability was 75.8±1.4% with a similar 3h attachment efficiency also observed, indicating successful hMSC recovery, and attachment. This approach therefore demonstrates that once an hMSC line and appropriate medium have been selected for production, multiple unit operations can be integrated to generate an animal component-free hMSC production process from expansion through to cryopreservation.
机译:人间充质干细胞(hMSC)治疗目前正在通过临床开发进行中,推动了对一致,经济高效的生产工艺的需求,以满足商业生产所需的批量。动物源性血清的使用在hMSC培养中很常见,但有许多缺点,例如供应有限,批次间差异,增加的监管负担,病原体传播的可能性以及流程优化范围的缩小。这些限制可能会影响一致的大规模流程的开发,因此必须加以解决。因此,这项工作的目的是在无血清hMSC生产工艺的系统开发中进行初步研究。在无血清培养基中,将人骨髓来源的hMSCs在纤连蛋白包被的无孔塑料微载体中于100mL搅拌的旋转烧瓶中扩增,密度为3×10cells.mL。 hMSCs是通过我们最近开发的技术成功收获的,该技术使用无动物的酶促细胞分离并伴随搅拌,然后过滤将hMSCs与微载体分离,收获后的生存力为99.63±0.03%。发现hMSC符合ISCT表征标准,并保持了hMSC的生长和集落形成潜能。将hMSC保持在收获后的悬浮液中,以模拟规模扩展过程的典型合并时间,并使用控制速率的冷冻过程将其冷冻保存在无血清载体溶液中。解冻后的存活率为75.8±1.4%,还观察到了类似的3h附着效率,表明hMSC成功恢复并附着。因此,该方法证明,一旦选择了hMSC系和合适的培养基进行生产,就可以整合多个单元操作,以生成从扩增到冷冻保存的无动物成分的hMSC生产过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号